Why Diagnostics Labs Get Competitor Market Share Wrong — and How Entity Resolution Fixes It

Ask a diagnostics commercial team what share of an account or a territory a named competitor holds, and you’ll usually get a confident number. Ask how that number was built, and the confidence tends to drop. In most cases, it was built by pulling claims tied to one obvious billing name for that competitor — and stopping there. That’s the moment most competitor market share estimates in diagnostics quietly go wrong.

This is a data-quality problem with a name: entity resolution. It sits underneath nearly every competitive claim a diagnostics or lab commercial team makes, and it’s rarely audited, because the output — a clean-looking share percentage — never signals that anything is missing.

Competitors Don’t Exist as One Entity in Claims Data

A diagnostics or reference lab rarely bills under a single, clean corporate name. Between legacy acquisitions, regional subsidiaries, specialty-testing arms, and separately enrolled billing NPIs and TINs, one competitor’s ordering volume is usually scattered across a dozen or more distinct entities in claims data. Some of those entities share almost nothing in their name with the parent brand.

If your analysis captures only the flagship entity — the one whose name matches what’s on the sales deck — you are not measuring the competitor’s share. You’re measuring a fraction of it, and you have no way of knowing how large a fraction. That’s the core problem entity resolution exists to solve: correctly mapping every legal, billing, and specialty entity a competitor operates into a single, consistent definition before you calculate anything.

Why This Happens, and Why It’s Getting Worse

A few forces keep pulling competitor billing structures apart:

• M&A activity. Diagnostics and lab services see frequent acquisition and roll-up activity. Every deal can add a newly acquired entity’s billing identifiers to the competitor’s true footprint — identifiers that won’t obviously read as belonging to the parent company.
• Specialty carve-outs. Molecular, genomic, and esoteric testing lines are often billed through separate specialty entities, distinct from the core reference lab’s general billing.
• Regional and legacy naming. National labs frequently retain regional brand names for years after an acquisition, so the same competitor can appear under several unrelated-looking names depending on geography.
• Multiple billing NPIs per performing lab. Even within one legal entity, testing volume can route through several billing NPIs tied to different locations or service lines.

None of this is hidden with malicious intent — it’s simply how billing infrastructure accumulates in a consolidating industry. But it means a static, one-time list of “who this competitor is” goes stale fast.

What Getting It Wrong Actually Costs You

This isn’t a data-hygiene footnote — it flows directly into every decision built on top of the number:

• Understated competitor share makes a contested account look safer than it is, so account teams under-invest in defense until volume has already shifted.
• Overstated own share — the mirror-image error, if your own entities aren’t fully resolved either — makes a book of business look healthier than it is going into a forecast.
• Wrong territory sizing, because the addressable and contested volume in a territory is calculated against an incomplete competitor picture.
• Misdirected sales prioritization, since reps get pointed at “greenfield” physicians who are, in reality, already ordering heavily from a competitor entity the analysis never counted.

Every one of these downstream uses depends on the same upstream number: a competitor’s true, consolidated ordering share. Get that number wrong, and precision at every later step — penetration, white space, territory design — is precision applied to the wrong baseline.

What Real Entity Resolution Requires

Fixing this isn’t a one-time cleanup project; it’s a standing discipline with a few non-negotiable pieces:

A living competitor definition. Every relevant billing NPI, TIN, and specialty subsidiary tied to a competitor needs to be mapped to that competitor, and that map has to be revisited as M&A activity and re-brandings occur — not built once and left alone. The NPPES NPI Registry, maintained by CMS, is the authoritative public source for organizational NPIs and can confirm a subsidiary’s legal name and enumeration date, but it won’t tell you which subsidiaries belong to which parent — that mapping has to be built and maintained separately.

Consistency across competitors. The same resolution standard has to apply to every competitor in the analysis, not just the one you’re most worried about. Apples-to-apples share only holds if every lab in the comparison set is measured with the same completeness.

All-payer claims as the base layer. Entity resolution only matters if the underlying claims data is complete enough to reward it. Medicare-only data structurally excludes commercial and Medicaid volume, so even a perfectly resolved competitor entity is being measured against an incomplete pool of ordering.

A resolution layer that rolls up to accounts and physicians, not just competitors. Once competitor entities are resolved, that resolved volume still needs to tie back to the same accounts and ordering physicians your own volume is mapped to — otherwise you have two correct numbers that can’t be compared to each other.

A Worked Example

Picture a mid-sized oncology group in a territory you’re actively working. A simple claims pull against “Competitor Lab Inc.” shows them holding roughly 15% of the group’s send-out volume — worth watching, but not urgent.

Now resolve the entity properly. That 15% turns out to sit alongside another 20% billed through a molecular-testing subsidiary the competitor acquired two years ago, plus another 10% billed through a regional entity that still carries its pre-acquisition name. The real number isn’t 15% — it’s 45%. That’s not a minor correction; it changes the account from “watch” to “at risk,” and it changes what a rep should be doing in that building this quarter.

That’s not a rounding error — it’s the difference between an account a rep checks in on quarterly and one that needs a defense plan this week. And it’s a difference that was sitting in claims data the whole time, just spread across identifiers a flagship-only search never touched.

Getting Started

You don’t need to resolve every competitor everywhere at once. Start with the one or two competitors causing the most uncertainty in your highest-priority territory: build a complete, current entity map for them, all-payer claims underneath it, and roll the resolved share up to the account and physician level. Compare that corrected number against whatever you were using before — the gap itself will usually make the case for doing this everywhere else.

Alpha Sophia resolves competitor entities across billing NPIs, TINs, and specialty subsidiaries on top of all-payer claims, so diagnostics and reference-lab teams get a true, consolidated share number — not just the flagship entity’s slice of it. Book a demo to see your top competitors resolved.

Frequently Asked Questions

What is entity resolution in the context of diagnostics claims data? It’s the process of mapping every legal, billing, and specialty entity a competitor (or your own organization) operates under into a single, consistent definition, so ordering volume rolls up correctly before share is calculated.

Why don’t competitors show up as one entity in claims data? Because of M&A activity, specialty testing carve-outs billed separately, retained regional brand names after acquisition, and multiple billing NPIs per performing lab — all of which fragment one competitor’s volume across many identifiers.

What happens if I only measure a competitor’s flagship billing entity? You systematically understate their true share, because a meaningful portion of their volume is billed through subsidiaries, regional entities, or specialty arms that don’t obviously carry the parent brand’s name.

Does this affect my own share numbers too? Yes. If your own organization’s entities aren’t fully resolved, you can overstate your own share the same way you’d understate a competitor’s — the fix has to apply symmetrically.

How is entity resolution different from physician-level ordering data? Entity resolution fixes who counts as “the competitor” before share is calculated. Physician-level ordering data is a separate layer of analysis that shows which individual physicians inside an account are driving that share. The first has to be correct for the second to mean anything.

Why does all-payer claims data matter here specifically? A perfectly resolved competitor entity is still only as good as the claims pool underneath it. Medicare-only data excludes commercial and Medicaid volume, so even correct entity resolution is working with an incomplete picture without all-payer data.

How often does a competitor entity map need to be updated? As often as the competitor’s corporate structure changes — new acquisitions, re-brandings, or newly enrolled billing NPIs can all add volume that wasn’t previously mapped. Treat it as a maintained map, not a one-time build.

Can this change how “at risk” an account looks? Yes, often significantly. An account that looks lightly contested against a flagship-only competitor number can look genuinely at risk once subsidiary and regional entities are added in.

Is this only relevant for large national competitors? No. Regional and specialty labs also frequently operate multiple billing entities, particularly after any acquisition activity, so the same fragmentation risk applies at smaller scale too.

How do I know if my current competitor share numbers are undercounting? A practical test: pick your highest-priority competitor in one territory, fully resolve their entities, and compare the corrected share against what you were using before. A meaningful gap is a strong signal the same issue exists elsewhere.

Does entity resolution replace the need for physician-level data? No — they’re sequential, not substitutes. Resolve the entities first so the share number is accurate, then use physician-level ordering data to see which physicians inside the account are behind that share.

Where should we start if we’ve never done this before? Begin with one or two competitors in your most important territory, build a complete and current entity map for them, apply it to all-payer claims, and roll the corrected share up to the account and physician level before expanding further.